SCHEMBL8533262

SCHEMBL8533262

O=C1CC[C@H]2C(=O)c3cc(Br)ccc3O[C@H]2C1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PBRM1 Q86U86 1/20 0.47
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
CYP19A1 P11511 1/20 0.40
AR P10275 1/20 0.40
ESR2 Q92731 2/20 0.39
ESR1 P03372 1/20 0.39
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
HIF1A Q16665 1/20 0.37
ALDH1A1 P00352 3/20 0.34
LMNA P02545 1/20 0.33
POLB P06746 1/20 0.33
BCHE P06276 1/20 0.32
STS P08842 1/20 0.32
APP P05067 1/20 0.32
S100A4 P26447 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL877627 1.00 PBRM1 (0.47) PBRM1MEN1KMT2ACYP19A1AR
SCHEMBL8534978 1.00 PBRM1 (0.47) PBRM1MEN1KMT2ACYP19A1AR
SCHEMBL875271 0.81 PBRM1 (0.47) PBRM1MEN1KMT2ACYP19A1AR
SCHEMBL10209401 0.81 PBRM1 (0.47) PBRM1MEN1KMT2ACYP19A1AR
SCHEMBL9932654 0.81 PBRM1 (0.47) PBRM1MEN1KMT2ACYP19A1AR
SCHEMBL9931541 0.81 PBRM1 (0.47) PBRM1MEN1KMT2ACYP19A1AR
SCHEMBL8534502 0.78 PBRM1 (0.43) PBRM1MEN1KMT2ACYP19A1AR
SCHEMBL8534500 0.78 PBRM1 (0.43) PBRM1MEN1KMT2ACYP19A1AR
SCHEMBL9882174 0.78 PBRM1 (0.43) PBRM1MEN1KMT2ACYP19A1AR
SCHEMBL8531188 0.75 PBRM1 (0.43) PBRM1MEN1KMT2ACYP19A1AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120157448-A1 COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES GENENTECH, INC. 2012-06-21 US disclosed
WO-2012071458-A1 HETEROCYCLIC INHIBITORS OF BETA - SECRETASE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES ARRAY BIOPHARMA INC. (US) 2012-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157448-A1 COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES BACE1, PSEN1, PSEN2 PBRM1 3853/4885MEN1 3061/4885KMT2A 4037/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.